ara 290
Peptideexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2012 (NCT02070783)
Timeline
Indications
Mechanism of action
- ErythropoietinSupplementation
EPO supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- ara 290
- ara 290
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02039687 | Phase 2 | Jan 1, 2014 | Araim Pharmaceuticals, Inc. |
| NCT01933529 | Phase 2 | Oct 1, 2013 | Araim Pharmaceuticals, Inc., Karolinska Institute |
| NCT02070783 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2012 | Leiden University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Araim Pharmaceuticals, Inc. | For profit | 2 | 1 | 1 | 2013 |
| Karolinska Institute | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Leiden University | Academic/Hospital | 1 | 1 | 1 | 2012 |
3 organizations
Page 1 / 1